199 related articles for article (PubMed ID: 35978199)
21. Application of Small Cell Lung Cancer Molecular Subtyping Markers to Small Cell Neuroendocrine Carcinoma of the Cervix: NEUROD1 as a Poor Prognostic Factor.
Kim G; Kim M; Nam EJ; Lee JY; Park E
Am J Surg Pathol; 2024 Mar; 48(3):364-372. PubMed ID: 37981832
[TBL] [Abstract][Full Text] [Related]
22. Concordance of ASCL1, NEUROD1 and POU2F3 transcription factor-based subtype assignment in paired tumour samples from small cell lung carcinoma.
Denize T; Meador CB; Rider AB; Ganci ML; Barth JL; Kem M; Mino-Kenudson M; Hung YP
Histopathology; 2023 Dec; 83(6):912-924. PubMed ID: 37644667
[TBL] [Abstract][Full Text] [Related]
23. ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.
Hu C; Dong J; Liu L; Liu J; Sun X; Teng F; Wang X; Ying J; Li J; Xing P; Yang L
Thorac Cancer; 2022 Feb; 13(3):338-345. PubMed ID: 34931456
[TBL] [Abstract][Full Text] [Related]
24. SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures.
Tlemsani C; Pongor L; Elloumi F; Girard L; Huffman KE; Roper N; Varma S; Luna A; Rajapakse VN; Sebastian R; Kohn KW; Krushkal J; Aladjem MI; Teicher BA; Meltzer PS; Reinhold WC; Minna JD; Thomas A; Pommier Y
Cell Rep; 2020 Oct; 33(3):108296. PubMed ID: 33086069
[TBL] [Abstract][Full Text] [Related]
25. Tumor-derived Vimentin as a novel biomarker for distinct subtypes predicting adjuvant chemotherapy resistance and T-cell-inflamed phenotype in small cell lung cancer.
Deng C; Wang Y; Fu F; Li D; Zheng Q; Jin Y; Li Y; Chen H; Zhang Y
MedComm (2020); 2023 Oct; 4(5):e370. PubMed ID: 37789961
[TBL] [Abstract][Full Text] [Related]
26. YTHDF2 negatively correlates with tumor immune infiltration in small cell lung cancer.
Chen G; Ren D; Wang Y; Wang H; Zhang J; Yang S
J Mol Histol; 2023 Aug; 54(4):365-377. PubMed ID: 37357252
[TBL] [Abstract][Full Text] [Related]
27. YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype.
Owonikoko TK; Dwivedi B; Chen Z; Zhang C; Barwick B; Ernani V; Zhang G; Gilbert-Ross M; Carlisle J; Khuri FR; Curran WJ; Ivanov AA; Fu H; Lonial S; Ramalingam SS; Sun SY; Waller EK; Sica GL
J Thorac Oncol; 2021 Mar; 16(3):464-476. PubMed ID: 33248321
[TBL] [Abstract][Full Text] [Related]
28. Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy.
Shirasawa M; Yoshida T; Shiraishi K; Takigami A; Takayanagi D; Imabayashi T; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yotsukura M; Yoshida Y; Nakagawa K; Tsuchida T; Hamamoto R; Yamamoto N; Motoi N; Kohno T; Watanabe SI; Ohe Y
Lung Cancer; 2023 May; 179():107183. PubMed ID: 37037178
[TBL] [Abstract][Full Text] [Related]
29. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
[TBL] [Abstract][Full Text] [Related]
30. ASCL1 regulates super-enhancer-associated miRNAs to define molecular subtypes of small cell lung cancer.
Miyakawa K; Miyashita N; Horie M; Terasaki Y; Tanaka H; Urushiyama H; Fukuda K; Okabe Y; Ishii T; Kuwahara N; Suzuki HI; Nagase T; Saito A
Cancer Sci; 2022 Nov; 113(11):3932-3946. PubMed ID: 35789143
[TBL] [Abstract][Full Text] [Related]
31. BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation.
Chen H; Gesumaria L; Park YK; Oliver TG; Singer DS; Ge K; Schrump DS
Mol Cancer Res; 2023 Feb; 21(2):91-101. PubMed ID: 36378541
[TBL] [Abstract][Full Text] [Related]
32. In-depth proteomic analysis reveals unique subtype-specific signatures in human small-cell lung cancer.
Szeitz B; Megyesfalvi Z; Woldmar N; Valkó Z; Schwendenwein A; Bárány N; Paku S; László V; Kiss H; Bugyik E; Lang C; Szász AM; Pizzatti L; Bogos K; Hoda MA; Hoetzenecker K; Marko-Varga G; Horvatovich P; Döme B; Schelch K; Rezeli M
Clin Transl Med; 2022 Sep; 12(9):e1060. PubMed ID: 36149789
[TBL] [Abstract][Full Text] [Related]
33. Small cell lung cancer: Subtypes and therapeutic implications.
Wang WZ; Shulman A; Amann JM; Carbone DP; Tsichlis PN
Semin Cancer Biol; 2022 Nov; 86(Pt 2):543-554. PubMed ID: 35398266
[TBL] [Abstract][Full Text] [Related]
34. Molecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC?
Kawai H; Matsuoka R; Ito T; Matsubara D
Front Biosci (Landmark Ed); 2022 Mar; 27(3):108. PubMed ID: 35345340
[TBL] [Abstract][Full Text] [Related]
35. Molecular Classification of Extrapulmonary Neuroendocrine Carcinomas With Emphasis on POU2F3-positive Tuft Cell Carcinoma.
Koh J; Kim H; Moon KC; Lee C; Lee K; Ryu HS; Jung KC; Jeon YK
Am J Surg Pathol; 2023 Feb; 47(2):183-193. PubMed ID: 36253891
[TBL] [Abstract][Full Text] [Related]
36. Immune Cell Infiltration May Be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer.
Muppa P; Parrilha Terra SBS; Sharma A; Mansfield AS; Aubry MC; Bhinge K; Asiedu MK; de Andrade M; Janaki N; Murphy SJ; Nasir A; Van Keulen V; Vasmatzis G; Wigle DA; Yang P; Yi ES; Peikert T; Kosari F
J Thorac Oncol; 2019 Jul; 14(7):1286-1295. PubMed ID: 31078775
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors.
Shijubou N; Sumi T; Kubo T; Sasaki K; Tsukahara T; Kanaseki T; Murata K; Keira Y; Terai K; Ikeda T; Yamada Y; Chiba H; Hirohashi Y; Torigoe T
J Cancer Res Clin Oncol; 2024 Mar; 150(3):125. PubMed ID: 38483588
[TBL] [Abstract][Full Text] [Related]
38. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
[TBL] [Abstract][Full Text] [Related]
39. Integrated Immunohistochemical Study on Small-Cell Carcinoma of the Lung Focusing on Transcription and Co-Transcription Factors.
Sato Y; Okamoto I; Kameyama H; Kudoh S; Saito H; Sanada M; Kudo N; Wakimoto J; Fujino K; Ikematsu Y; Tanaka K; Nishikawa A; Sakaguchi R; Ito T
Diagnostics (Basel); 2020 Nov; 10(11):. PubMed ID: 33202998
[TBL] [Abstract][Full Text] [Related]
40. Galectin-9-based immune risk score model helps to predict relapse in stage I-III small cell lung cancer.
Chen P; Zhang L; Zhang W; Sun C; Wu C; He Y; Zhou C
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
